Advanced Proteome Therapeutics announced a collaboration with the National Research Council of Canada for the development of antibody-drug conjugates.
Advanced Proteome Therapeutics (TSXV:APC) announced a collaboration with the National Research Council of Canada for the development of antibody-drug conjugates.
As quoted in the press release:
Through recently signed collaborations, APC’s efforts are centered on antibody candidates that will be linked to drugs or toxins for the purpose of treating advanced solid tumors such as ovarian cancer, breast cancer, and non-small cell lung cancer, areas of ongoing therapeutic need in a more effective way.
“APC and the NRC will join forces to accurately evaluate the extent to which a drug (or toxin) has been attached to an antibody, validating our proprietary linker technology,” stated Allen Krantz, APC’s Founder and Chief Science Officer. “Scaling up and testing of the drug-linked candidates we produce, in cell models, will determine their potential as therapies and move APC one step closer to a commercialization.”